Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Prospective, Randomized, Double-Arm, Deferred Treatment, Open Label, Repeat Dose, Safety and Efficacy Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease

NCT02836574 is registered in ClinicalTrials.gov with Prokidney as lead sponsor.

NCT NCT02836574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02836574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Prospective, Randomized, Double-Arm, Deferred Treatment, Open Label, Repeat Dose, Safety and Efficacy Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease
Lead sponsor
Prokidney
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2016
Completion date
December 31, 2023
Enrollment
83 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, type 2 diabetes mellitus